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Background:  Mesenchymal stem cells (MSC) repair infarcted hearts mainly through paracrine mechanisms. It is known that cell 
engraftment is poor and this limits the release of paracrine mediators over time and MSC efficacy. We tested if a PEG hydrogel containing 
heparin, which is able to bind soluble factors (SF), can ameliorate MSC engraftment and help in fine-tuning the release of SF produced by 
the cells.
methods:  We synthesized an enzymatically degradable PEG hydrogel containing heparin (H-HG). H-HG or control PEG hydrogel (PEG-
HG) were incubated with bFGF, highly expressed in MSC, and its release was quantified up to day 18. Rat MSC were seeded into the 
hydrogel during the polymerization phase; cell viability and sprouting were evaluated over time. Cytoprotective action of the hydrogel on 
MSC exposed to hypoxia was measured by LIVE/DEAD assay. Finally, myocardial infarction (MI) was induced in rats by permanent ligation 
of the coronary artery. One week later, saline, MSC or MSC/H-HG were injected in the infarct zone. Echo was performed immediately 
before and 1 week after treatment. MSC engraftment and viability were determined 1 week after delivery.
results:  Concentration of bFGF in the medium was significantly higher in the presence of H-HG compared with PEG-HG at each time 
point tested, and the amount of bFGF grew over time; this indicates that H-HG can bind and release putative paracrine factors better than 
PEG-HG. Survival of MSC in H-HG was higher than 90%. Sprouting cells were observed after 1 week and further increased at 1 month. 
In addition, hydrogel increased viability of MSC exposed to hypoxia (+18.5% vs MSC alone, p<0.01). Co-injection of MSC and H-HG 
resulted in improvement of fractional shortening compared with both MSC alone and saline (p<0.001). Importantly, H-HG increased MSC 
engraftment, reduced the activation of apoptotic mechanisms and ameliorated cardiac remodelling.
conclusion:  Our data suggest that H-HG binds and releases SF in a controlled manner and protects MSC from hypoxic insult. Most 
importantly, administration of MSC in combination with H-HG improves cardiac function and remodelling in a model of non-reperfused MI 
by increasing MSC engraftment and by limiting cell death.
